Your session is about to expire
← Back to Search
Olaparib for Breast Cancer
Study Summary
This trial is testing the side effects and best dose of olaparib when given with hyperthermia, which is a treatment that raises the temperature of the body to kill cancer cells, in patients with breast cancer that has come back in the chest wall.
- Breast Cancer
- Chest Wall Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 154 Patients • NCT02184195Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have received a bone marrow transplant from someone else or a double umbilical cord blood transplant in the past.You have had cancer in the past, but it has been successfully treated and there has been no sign of it coming back for at least 5 years. There are some types of cancer that are not included in this criteria, such as non-melanoma skin cancer, very early stage cervical cancer, and a specific type of early stage endometrial cancer.You are allergic to hyperthermia treatment.Women who are currently breastfeeding.You have breast cancer that has come back on the chest wall, regardless of certain protein levels in the tumor.Your body mass index (BMI) should be between 15 and 50 when you agree to participate.You have received treatment with a PARP inhibitor called olaparib before.Your disease is getting worse quickly.You have experienced menopause caused by chemotherapy, and it has been more than one year since your last period.
- Group 1: Treatment (olaparib, hyperthermia)
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What adverse effects are associated with Olaparib usage?
"Since this is a Phase 1 trial, there is minimal clinical data backing up the safety and effectiveness of Olaparib - thus it was rated as a 1."
Are there any recruitment opportunities for this research project presently available?
"Indications from clinicaltrials.gov suggest that this research project is no longer recruiting new participants, having first been published on May 20th 2019 and last updated October 18th 2021. Nonetheless, 5710 other trials are actively seeking contributors at the present moment."
What medical conditions has Olaparib been found to effectively address?
"Olaparib is the most common treatment for advance directives, but it can also be used to manage malignant neoplasm of ovary, primary peritoneal cancer, and hallucinations with somatic symptoms."
Am I eligible to join this medical research endeavor?
"This trial seeks to enrol 3 individuals who suffer from hyperthermia and fall within the age range of 18-80. Eligibility necessitates a ECOG performance status between 0-1, regardless of ER/PR/HER2 receptor statuses, and instances of breast cancer recurrence on the chest wall."
Is this trial a precedent-setting venture?
"Olaparib has been actively researched since the first phase 1 drug trial in 2005, which was supported by AstraZeneca. Today there are 188 ongoing studies for Olaparib across 1469 cities and 60 nations."
What is the cap for participants in this research project?
"No, enrollment for this study has concluded. The initial listing was posted on May 20th 2019 and the information was last updated October 18 2021. Currently there are 5522 studies related to hyperthermia admitting patients and 188 trials involving Olaparib looking for participants."
Is there an age cap on the participants of this clinical study?
"This research study seeks participants aged between 18 years and 80 years."
Are there other research endeavors that have utilized Olaparib?
"Presently, 188 studies are ongoing to explore the efficacy of Olaparib. Of these trials, 27 have advanced to Phase 3. Most research is conducted in Houston, Texas; however there exists a total of 9255 clinical trial sites for this medication around the world."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger